Objective: For extended-release drugs with multi-compartment kinetics, such as topiramate, effective half-life (t) may be a more clinically relevant parameter than elimination half-life (t). Using topiramate as a real-life example, the objective was to compare these half-life values for immediate- and extended-release topiramate (TPM-IR and USL255, respectively) to understand how drug pharmacokinetics may impact drug dosing recommendations.
Methods: The t and t for USL255 and TPM-IR were compared using data from a phase I study (N=36) of 200mg USL255 administered once daily (QD) or TPM-IR twice daily (BID); effect of sampling duration on t was investigated. To further explore the relationship between half-life and dosing, steady-state PK was simulated for USL255 and TPM-IR.
Results: As previously reported, mean t was similar between USL255 (80.2h) and TPM-IR (82.8h); TPM-IR t was ∼4 times longer than reported in the Topamax label (21h). In contrast, USL255 displayed a 1.5 fold longer t (55.7 vs 37.1h for TPM-IR). When t was calculated from 48 to 336h, values ranged from 28.8 to 82.8h. Simulated steady-state PK profiles of USL255 QD exhibited reduced plasma fluctuations during a dosing interval vs TPM-IR QD or BID.
Significance: As expected for the same moiety, t of USL255 and TPM-IR were similar; however, the longer t for USL255 better approximates differences in recommend dosing (QD USL255 vs BID TPM-IR). Further, sampling duration impacted t, diminishing its predictive value for determining dose regimens; sampling-time differences may also explain t discrepancy between TPM-IR here versus Topamax label. As expected, steady-state simulations confirm that although TPM-IR has a long t, taking TPM-IR QD would lead to large plasma fluctuations. These data demonstrate that t may be less clinically meaningful than t and using t for some drugs may lead to erroneous conclusions regarding dosing regimens.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.eplepsyres.2016.10.020 | DOI Listing |
J Clin Pharm Ther
October 2021
Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
What Is Known And Objective: Extended-release topiramate (TPM-XR) was recently approved for the treatment of epilepsy, but there is only limited real-world information on the clinical usefulness of TPM-XR in epilepsy patients. We investigated the usefulness of TPM-XR in clinical practice by analysing the retention of TPM-XR in adult epilepsy patients.
Methods: We performed a single-centre retrospective study covering two years.
J Comp Eff Res
November 2018
Indegene TTM, 222 Chastain Meadows Ct #300, Kennesaw, GA 30144, USA (at time of study).
Aim: Examine clinical profile of extended-release topiramate (Trokendi XR) and compare treatment-emergent adverse events (TEAEs) associated with Trokendi XR versus previous immediate-release topiramate (TPM-IR) treatment.
Patients & Methods: Pilot retrospective study analyzing data extracted from medical charts of patients ≥6 years of age prescribed Trokendi XR.
Results: Trokendi XR was the most commonly used to prevent migraine.
Epilepsy Res
January 2017
University of Kentucky, Kentucky Neuroscience Institute, 740 South Limestone Kentucky Clinic, First floor, Wing C, Lexington, KY 40536, United States. Electronic address:
Objective: For extended-release drugs with multi-compartment kinetics, such as topiramate, effective half-life (t) may be a more clinically relevant parameter than elimination half-life (t). Using topiramate as a real-life example, the objective was to compare these half-life values for immediate- and extended-release topiramate (TPM-IR and USL255, respectively) to understand how drug pharmacokinetics may impact drug dosing recommendations.
Methods: The t and t for USL255 and TPM-IR were compared using data from a phase I study (N=36) of 200mg USL255 administered once daily (QD) or TPM-IR twice daily (BID); effect of sampling duration on t was investigated.
Epilepsy Behav
November 2015
Division of Pediatric Neurology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, TN, USA. Electronic address:
Background: Once-daily extended-release (XR) antiepileptic drugs (AEDs) offer potential adherence and tolerability advantages over their BID immediate-release (IR) counterparts. However, patients with epilepsy will inevitably be at least occasionally nonadherent with a prescribed dosing regimen, regardless of formulation. Although perturbations in plasma concentrations due to dosing irregularities may have clinical consequences for AEDs with concentration-response relationships, clinical studies that deliberately expose patients to specific dosing irregularities in order to assess the effect on plasma concentrations and determine appropriate corrective actions would be unethical.
View Article and Find Full Text PDFEpilepsia
August 2013
Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
Purpose: Compare the pharmacokinetic (PK) profiles of immediate- and extended-release formulations of topiramate (TPM) in healthy subjects following multiple dosing, and evaluate maintenance of topiramate exposures after switching formulations.
Methods: A randomized, open-label, single-center, two-way crossover, multiple-dose study comparing the steady-state PK profile of once-daily extended-release topiramate (USL255) to immediate-release topiramate (TPM-IR) administered twice-daily. The TPM PK profile was evaluated using standard PK parameters (e.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!